Omar Mian, MD, PhD, discusses the ongoing investigation into the synchronous up-front setting of metastatic prostate cancer.
Omar Mian, MD, PhD, radiation oncologist, physician/scientist, associate staff, Taussig Cancer Institute, Cleveland Clinic, discusses the ongoing investigation into the synchronous up-frontsetting of metastatic prostate cancer.
There are a lack of data on the clinical benefit of metastasis-directed regimens, creating an unmet medical need, Mian says. However, ongoing research is evaluating intensified hormone therapies, such as GnRH agonists and selective androgen receptor modulators, Mian explains. Radiation at several secondary tumor sites in addition to the prostate is also being investigated, Mian adds.
The phase 2/3 STAMPEDE trial (NCT00268476) has opened new investigational arms evaluating treatment with abiraterone acetate (Zytiga) and radiotherapy, respectively, Mian continues. Additionally, several prospective clinical trials are investigating the use of radiation therapy for nodal recurrences within prostate cancer. Until more data can be collected, clinicians should be selective in their use of ablative radiation as an induction therapy, Mian concludes.